|
Jul 31
|
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
|
|
Jun 24
|
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
|
|
Jun 17
|
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
|
|
May 14
|
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 1
|
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
|
|
Apr 29
|
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
|
|
Mar 28
|
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 26
|
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
|
|
Mar 19
|
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
|
Mar 19
|
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
|
|
Mar 15
|
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
|
Mar 8
|
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
|
|
Mar 1
|
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
|
|
Feb 29
|
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
|
|
Jan 10
|
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
|
|
Jan 9
|
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
|
|
Dec 27
|
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
|
|
Dec 21
|
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
|
|
Dec 4
|
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
|
|
Nov 29
|
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
|